CO2020013468A2 - Agentes de unión a c3 y métodos para su uso - Google Patents

Agentes de unión a c3 y métodos para su uso

Info

Publication number
CO2020013468A2
CO2020013468A2 CONC2020/0013468A CO2020013468A CO2020013468A2 CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2 CO 2020013468 A CO2020013468 A CO 2020013468A CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2
Authority
CO
Colombia
Prior art keywords
binding agents
methods
encode
antibodies
compositions
Prior art date
Application number
CONC2020/0013468A
Other languages
English (en)
Inventor
Dana Yen Mei Duey
Zhonghao Liu
Jie Tang
Yan Wang
Yiyuan Yin
Wenwu Zhai
Jared Martin Higbee
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CO2020013468A2 publication Critical patent/CO2020013468A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona agentes de unión, tales como anticuerpos (que incluyen fragmentos variables de cadena simple), que se unen específicamente al componente del complemento C3, que incluye el C3 humano, composiciones que lo comprenden y métodos para su uso. La descripción también proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que los comprenden.
CONC2020/0013468A 2018-04-03 2020-10-26 Agentes de unión a c3 y métodos para su uso CO2020013468A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652253P 2018-04-03 2018-04-03
PCT/US2019/025123 WO2019195136A1 (en) 2018-04-03 2019-04-01 C3-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2020013468A2 true CO2020013468A2 (es) 2020-11-10

Family

ID=66630340

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013468A CO2020013468A2 (es) 2018-04-03 2020-10-26 Agentes de unión a c3 y métodos para su uso

Country Status (18)

Country Link
US (3) US11136381B2 (es)
EP (1) EP3790897A1 (es)
JP (2) JP7477457B2 (es)
KR (1) KR20200138290A (es)
CN (1) CN112105638A (es)
AR (1) AR117565A1 (es)
AU (1) AU2019248557A1 (es)
BR (1) BR112020019907A2 (es)
CA (1) CA3093356A1 (es)
CL (2) CL2020002522A1 (es)
CO (1) CO2020013468A2 (es)
IL (1) IL277404A (es)
MX (1) MX2020010323A (es)
PE (1) PE20212132A1 (es)
PH (1) PH12020500664A1 (es)
SG (1) SG11202008897SA (es)
TW (1) TWI833742B (es)
WO (1) WO2019195136A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093356A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
WO2021226442A2 (en) 2020-05-08 2021-11-11 Ngm Biopharmaceuticals, Inc. Therapeutic uses of c3-binding agents
EP4213808A4 (en) * 2020-09-21 2024-05-22 Apellis Pharmaceuticals, Inc. METHODS OF TREATMENT OF EYE DISORDERS
KR20240117157A (ko) 2021-12-22 2024-07-31 씨디알-라이프 아게 항-c3 항체 및 이의 항원 결합 단편 및 눈 또는 안구 질환 치료를 위한 이의 용도
WO2024086555A1 (en) * 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies
CN117447601B (zh) * 2023-12-22 2024-03-08 北京索莱宝科技有限公司 猪IgM的抗体、抗体组合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002524533A (ja) * 1998-09-10 2002-08-06 ザ ユニヴァーシティー オブ ヴァージニア パテント ファウンデーション 癌細胞に診断薬及び治療薬をデリバリーするためのＣ３ｂ（ｉ）に対する抗体
AU2003271681A1 (en) * 2002-10-04 2004-04-23 Sanquin Blood Supply Foundation Amsterdam Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
WO2006012621A2 (en) 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
EP1853299A4 (en) 2005-01-14 2009-11-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
ES2546304T3 (es) 2009-05-20 2015-09-22 Toray Industries, Inc. Péptidos permeables para la membrana celular
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
EP2571899A1 (en) 2010-05-18 2013-03-27 Syddansk Universitet Novel c3c epitope, antibodies binding thereto, and use thereof
USRE49339E1 (en) 2010-06-22 2022-12-20 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3D fragment of complement component 3
CN104220453B (zh) 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途
CA2934462A1 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
MA51519A (fr) 2014-05-05 2020-11-11 Regeneron Pharma Animaux c5 et c3 humanisés
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
CA2969847A1 (en) * 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US20180346531A1 (en) 2015-09-15 2018-12-06 Regents Of The University Of California Compositions and methods for delivering biotherapeutics
RU2770099C2 (ru) 2015-10-07 2022-04-14 Апеллис Фармасьютикалс, Инк. Схемы введения
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
CA3093356A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof

Also Published As

Publication number Publication date
JP2021520195A (ja) 2021-08-19
US20220119508A1 (en) 2022-04-21
BR112020019907A2 (pt) 2021-01-05
US11136381B2 (en) 2021-10-05
JP2024056851A (ja) 2024-04-23
PH12020500664A1 (en) 2021-06-07
CN112105638A (zh) 2020-12-18
IL277404A (en) 2020-11-30
CA3093356A1 (en) 2019-10-10
KR20200138290A (ko) 2020-12-09
TW202003559A (zh) 2020-01-16
AU2019248557A1 (en) 2020-09-24
AR117565A1 (es) 2021-08-18
CL2021002039A1 (es) 2022-04-01
WO2019195136A1 (en) 2019-10-10
US20190322730A1 (en) 2019-10-24
PE20212132A1 (es) 2021-11-05
MX2020010323A (es) 2021-01-08
SG11202008897SA (en) 2020-10-29
US20230382985A1 (en) 2023-11-30
JP7477457B2 (ja) 2024-05-01
US11767359B2 (en) 2023-09-26
RU2020135712A (ru) 2022-05-04
TWI833742B (zh) 2024-03-01
EP3790897A1 (en) 2021-03-17
CL2020002522A1 (es) 2021-02-26

Similar Documents

Publication Publication Date Title
CO2020013468A2 (es) Agentes de unión a c3 y métodos para su uso
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
CO2017012342A2 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit)
CO2018000992A2 (es) Anticuerpos anti-pd-1 novedosos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CO2017001558A2 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
CO2021013279A2 (es) Anticuerpos de cadena pesada que se unen al psma
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
MX2020004561A (es) Anticuerpos biespecificos que se unen a alk-1 y bmpr-2.
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
CO2022018537A2 (es) Agentes de unión a lair-1 y métodos para su uso
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
DOP2019000098A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CL2020001629A1 (es) Anticuerpos de unión a hla-a2/wt1.
AR093620A1 (es) Anticuerpos bmp-6